PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of data to support the conversion of a previously submitted provisional patent covering the biosynthetic production of methylated tryptamine derivatives including N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine as well as other related products.
“We are proud of the strength of our intellectual property portfolio, safeguarding our advancement of biosynthetic production of psycho-targeted molecules. This most recent filing of data extends our coverage to include DMT and 5-MeO-DMT,” “While these methylated tryptamine derivatives are well known, this filing covers numerous novel compounds that we expect will allow us to proceed with clinical development and build on our work to potentially improve mental and neurological healthcare for patients.”
Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical Officer
The patent information submitted includes data concerning host strains, production methodology, and processes of production that support and allow PsyBio’s novel methodology to be successful.
“PsyBio continues to demonstrate its leadership in the biosynthetic development field through our continued commitment to strengthen our intellectual property portfolio, while also promoting scientific and methodologic advancements in the field,” stated Evan Levine, PsyBio’s Chief Executive Officer. “Intellectual property protection is paramount for our Company and our shareholders.”
About PsyBio Therapeutics Corp.
PsyBio Therapeutics is an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.